DXB 1.28% 38.5¢ dimerix limited

Ann: AGM Presentation, page-62

  1. 2,011 Posts.
    lightbulb Created with Sketch. 455
    Great post.

    The poster you responding to is clearly a downramper.

    Its not that we don't value other side of the coin, but comments like this "I'm aware of for this asset is their diabetes kidney disease study, but I read that flopped" clearly shows misrepresentation of facts.

    On the basis of the "Flopped" DKD trial, Dimerix announced that it has entered into an agreement with the Australian Centre for Accelerating Diabetes Innovation (ACADI) to commence a clinical trial on diabetic kidney disease (expected to commence Q4 this year).

    The reason it hasn't progressed coz Dimerix is fully focused on FSGS...I am sure we will hear about DKD and COPD in due course...
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.